Breo Ellipta (fluticasone furoate/vilanterol trifenatate) is a prescription drug used to treat chronic obstructive pulmonary disease (COPD) and asthma. Breo Ellipta’s cost may depend on factors such ...
BREO ELLIPTA (fluticasone furoate and vilanterol) Inhalation Powder Breo Ellipta (fluticasone furoate/vilanterol; GlaxoSmithKline and Theravance) has been made available for chronic obstructive ...
If you have a certain kind of lung condition, your doctor might suggest Breo Ellipta as a treatment option for you. Breo Ellipta is a prescription drug used to treat chronic obstructive pulmonary ...
GlaxoSmithKline and Theravance’s Breo has been recommended for approval by an FDA advisory committee for asthma, but only in adults. Breo is already approved to treat chronic obstructive pulmonary ...
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 30, 2015) - GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug ...
GlaxoSmithKline’s new long-term, once-daily, maintenance therapy for chronic obstructive pulmonary disease (COPD) has been approved in the US. The FDA licensed Breo Ellipta to treat airflow ...
DUBLIN--(BUSINESS WIRE)--The "Breo Ellipta" report has been added to ResearchAndMarkets.com's offering. Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol ...
The FDA granted approval to GlaxoSmithKline's ($GSK) new respiratory drug Breo Ellipta. By itself, that's a solid victory for GSK, which needs to build up its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback